Physician profile
Joseph K Samaha
NPI 1407833965
$4,046.51
in general payments reported to CMS, 2019-2025
23 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,442 · 2020: $212 · 2021: $231 · 2022: $608 · 2023: $623 · 2024: $755 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $683.12 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $664.87 | 2019-2024 | |
| Amgen INC. | $653.72 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $485.28 | 2019-2025 | Eliquis, Camzyos |
| Philips North America LLC | $338.47 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Cm9) Amb Mon & Diag Und |
| Sanofi-Aventis U.S. LLC | $197.73 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $163.76 | 2019-2022 | |
| Chiesi USA, INC. | $147.74 | 2019 | |
| Abbott Laboratories | $147.45 | 2019-2024 | Cardiomems, Confirm Rx |
| Boston Scientific Corporation | $134.22 | 2019-2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.42 | 2020-2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $64.62 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $40.01 | 2019-2021 | |
| Esperion Therapeutics, INC. | $37.97 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $29.90 | 2024 | Arcalyst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $29.44 | 2022-2023 | Verquvo |
| Cvrx, INC. | $28.76 | 2021-2022 | |
| Avinger INC. | $24.45 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.38 | 2019 | |
| Daiichi Sankyo INC. | $22.33 | 2024 | Injectafer |
| Kiniksa Pharmaceuticals, Ltd. | $18.90 | 2022 | |
| Ge Healthcare | $18.88 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $18.09 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Samaha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.